Pharmacoeconomic benefits of almotriptan in the acute treatment of migraine

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 8, Issue 2, 2008, Pages 105-110

  Freitag, Frederick G ^a,b,c  

^a DIAMOND HEADACHE CLINIC   (United States)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c MIDWESTERN UNIVERSITY   (United States)

Author keywords

Acute treatment; Almotriptan; Disability; Early intervention; Migraine; Presenteeism; Productivity

Indexed keywords

ALMOTRIPTAN; CAFERGOT; ELETRIPTAN; FROVATRIPTAN; NARATRIPTAN; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

ABSENTEEISM; ANALGESIA; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; EARLY INTERVENTION; HEADACHE; HEALTH ECONOMICS; HUMAN; LOW DRUG DOSE; MEDICAID; MIGRAINE; OCCUPATIONAL HEALTH; PAIN ASSESSMENT; PRODUCTIVITY; QUALITY OF LIFE INDEX; RECOMMENDED DRUG DOSE; THORAX DISEASE; UNSPECIFIED SIDE EFFECT; WORK DISABILITY; WORK ENVIRONMENT;

EID: 46949091363     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.8.2.105     Document Type: Article

References (18)

1. Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. Headache 43, 171-178 (2003).
2. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358, 1668-1675 (2001).
3. Gallagher R. What do patients want from acute migraine treatment? Cephalalgia 24(Suppl. 2), 8-15 (2004).
4. Ferrari MD, Goadsby PJ, Lipton RB et al. The use of multiattribute decision models in evaluating triptan treatment options in migraine. J. Neurol. 252, 1026-1032 (2005).
5. Daez FI, Straube A, Zanchin G. Patient preference in migraine therapy. A randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan. J. Neurol. 254, 242-249 (2007).
6. Mathew NT. Efficacy and tolerability of almotriptan in controlled clinical trials. Eur. Neurol. 53(Suppl. 1), 29-33 (2005).
7. Pascual J. Efficacy and tolerability of almotriptan in post-marketing surveillance studies. Eur. Neurol. 53(Suppl. 1), 34-40 (2005).
8. Mathew NT, Finlayson G, Smith TR et al. Early intervention with almotriptan: results of the AEGIS trial (Axert Early Migraine Intervention Study). Headache 47, 189-198 (2007).
9. Freitag FG, Finlayson G, Rapoport et al. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from the Axert 12.5 mg Time Versus Intensity Migraine Study (AIMS). Headache 47, 519-530 (2007).
10. Lainez M. Clinical benefits of early triptan therapy for migraine. Cephalalgia 24(Suppl. 2), 24-30 (2004).
11. Kelman L, Von Seggern RL. Using patient-centered endpoints to determine the cost-effectiveness of triptans for acute migraine therapy. Am. J. Ther. 13, 411-417 (2006).
12. Williams P, Reeder CE. A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point. J. Manag. Care Pharm. 10, 259-265 (2004).
13. Gori S, Morelli N, Acuto G et al. A pharmacoeconomic evaluation of oral triptans in the treatment of migraine in Italy. Minerva Med. 97, 467-477 (2006).
14. Mullins CD, Subedi PR, Healey PJ, Sanchez RJ. Economic analysis of triptan therapy for acute migraine: a Medicaid perspective. Pharmacotherapy 27, 1092-1101 (2007).
15. Lainez MJ, Galavan J, Heras J, Vila C. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur. J. Neurol. 14, 269-275 (2007).
16. Lofland JH, Nash DB. Oral serotonin receptor agonists: a review of their cost effectiveness in migraine. Pharmacoeconomics 23, 259-274 (2005).
17. McCormack PL, Foster RH. Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine. Pharmacoeconomics 23, 283-298 (2005).
18. Vicente-Herrero T, Burke TA, Lainez MJ. The impact of a worksite migraine intervention program on work productivity, productivity costs, and non-workplace impairment among Spanish postal service employees from an employer perspective. Curr. Med. Res. Opin. 20(11), 1805-1814 (2004).